In May 2022, registration for the 11th China Innovation and Entrepreneurship Competition (Jilin Region) began. This marked the seventh time that the Beikejian Changchun Beihu Science Park has hosted this national innovation and entrepreneurship event. Over the past seven years, the Beihu Science Park has witnessed over 2,700 enterprises participate in the competition, provided more than 20 training sessions for entrepreneurs, and accumulated over 500 hours of training.
Over these seven years, Beikejian Changchun Beihu Science Park has witnessed the excitement of Jilin Province's first national competition second prize, as well as the journey of numerous entrepreneurial projects from their early stages to rapid growth. On the occasion of the 11th Innovation and Entrepreneurship Competition registration, as the host of the event, Beikejian Changchun Beihu Science Park visited several companies that participated in previous competitions to learn about their entrepreneurial experiences and current operations, hoping to energize and inspire the companies preparing for this year’s competition with their personal stories and insights.
Horizon New Biology Pharmaceuticals (Changchun) Co., Ltd.
Third Prize in the Start-up Group of the 10th China Innovation and Entrepreneurship Competition (Jilin Region), and Outstanding Award in the Biopharmaceutical Industry at the National Competition of the 10th China Innovation and Entrepreneurship Competition.
The company was founded in August 2020 as a research-driven high-tech enterprise. With technological innovation as the cornerstone of its development, it has a high-level research and development team led by PhD scientists, committed to developing first-in-class cancer drugs.
In 2021, the company participated in the 10th China Innovation and Entrepreneurship Competition with its "Quadruple-Stranded DNA Cancer New Drug" project, winning the Third Prize in the Start-up Group of the Jilin Region and the Outstanding Award in the Biopharmaceutical Industry at the National Competition.
General Manager Xu Hong said: “Participating in this competition has broadened our horizons. We were fortunate to reach the national competition, where we had the opportunity to exchange ideas with outstanding enterprises from across the country and understand their development strategies. This has helped improve our company's operational level. Through the competition, we also found business partners and potential investors. Moreover, winning the award enhanced our company’s image, making our promotional efforts more persuasive.” As a participating company, we hope that more enterprises will boldly participate. Taking part in the competition itself is an opportunity to strengthen a company’s capabilities and a valuable learning experience.
In the future, the company will continue to focus on nucleic acid drugs, developing a series of innovative nucleic acid-targeted drugs, and further expanding its drug pipeline. The company is also committed to developing methods for targeted therapy using photosensitive compounds. It will actively engage in collaborations with top domestic and international universities and research institutions, establishing a technology innovation system based on enterprise leadership, market orientation, and integration of industry, academia, and research.